A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 47/32 (2006.01)
Patent
CA 2540202
The present invention provides methods and formulations for the treatment and prevention of cerebrovascular and cardiovascular diseases and disorders. The present invention is based, at least in part, on the discovery that administering to a subject a formulation comprising an agonist of endothelial nitric oxide synthase (eNOS), such as an HMG-CoA reductase inhibitor, and a formulation comprising a precursor of NO, such as L-arginine, may be used to treat or prevent cerebrovascular and/or cardiovascular diseases or disorders.
L'invention concerne des procédés et des formulations pour le traitement et la prévention de maladies et troubles cérébrovasculaires et cardiovasculaires. L'invention est basée, au moins partiellement, sur la découverte reposant sur le fait que l'administration à un sujet, d'une formulation comprenant un agoniste de synthase d'oxyde nitrique endothélial (eNOS), tel qu'un inhibiteur de réductase de HMG-CoA, et d'une formulation comprenant un précurseur de NO, tel que la L-arginine, peut être utilisée pour le traitement ou la prévention de maladies ou de troubles cérébrovasculaires et/ou cardiovasculaires.
Enos Pharmaceuticals Inc.
Palmetto Pharmaceuitcals Llc
Riches Mckenzie & Herbert Llp
LandOfFree
Sustained release l-arginine formulations and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sustained release l-arginine formulations and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release l-arginine formulations and methods of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1537850